CLN5 and glioblastoma: BMPs are considered potent inhibitors of glioblastoma during development, and BMP treatment can decrease the tumorigenicity of glioblastoma in vivo [22, 36–38], BMPs negatively regulate stemness and induce differentiation via activation of the Smad signaling cascade [21].